Provided by Tiger Fintech (Singapore) Pte. Ltd.

Jasper Therapeutics

5.94
-0.0700-1.16%
Post-market: 5.85-0.0900-1.52%19:22 EDT
Volume:223.57K
Turnover:1.34M
Market Cap:89.23M
PE:-1.13
High:6.10
Open:6.05
Low:5.86
Close:6.01
Loading ...

Promising Outlook for Jasper Therapeutics: Buy Rating Amidst Potential Upside and Strategic Developments

TIPRANKS
·
03 Mar

Jasper Therapeutics presents updated data from Phase 1b/2a BEACON study

TIPRANKS
·
02 Mar

RBC Capital Sticks to Their Buy Rating for Jasper Therapeutics (JSPR)

TIPRANKS
·
02 Mar

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

GlobeNewswire
·
02 Mar

Buy Recommendation for Jasper Therapeutics: Promising Developments in Briquilimab’s Phase 2b Program

TIPRANKS
·
01 Mar

Jasper Therapeutics Inc expected to post a loss of $1.26 a share - Earnings Preview

Reuters
·
28 Feb

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

GlobeNewswire
·
28 Feb

Jasper Therapeutics: Strategic Advancements and Promising Clinical Efficacy Drive Buy Rating

TIPRANKS
·
28 Feb

Promising Data from Jasper Therapeutics’ BEACON and SPOTLIGHT Studies Justify Buy Rating for Briquilimab

TIPRANKS
·
28 Feb

Jasper Therapeutics Q4 EPS $(1.62) Misses $(1.23) Estimate

Benzinga
·
27 Feb

Jasper Therapeutics Q4 Income From Operation USD -25.285 Million

THOMSON REUTERS
·
27 Feb

Press Release: Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

Dow Jones
·
27 Feb

Jasper Therapeutics to Present at Upcoming March Investor Conferences

GlobeNewswire
·
26 Feb

Jasper Therapeutics (JSPR) Gets a Buy from UBS

TIPRANKS
·
13 Feb

Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

GlobeNewswire
·
10 Feb

Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

GlobeNewswire
·
05 Feb

Jasper Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
10 Jan

Jasper Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
09 Jan

Jasper Therapeutics price target lowered to $48 from $68 at RBC Capital

TIPRANKS
·
09 Jan

RBC Cuts Price Target on Jasper Therapeutics to $48 From $68, Keeps Outperform, Speculative Risk

MT Newswires Live
·
09 Jan